EUVIMEDEUVIMED entdecken
Crossref

Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)

Nicole Casasanta, Rima Patel, Samantha Raymond, Melanie W Kier, Julia Blanter, Sophie Sohval, Malin Hovstadius, Catherine Wu, Brittney Zimmerman, Krystal Cascetta, Emilia Bagiella, Amy Tiersten

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Nicole Casasanta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ncasasanta19@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMiddle AgedRetrospective StudiesAdultChemotherapy, AdjuvantGene Expression ProfilingAgedPrognosisBiomarkers, TumorAntineoplastic Agents, HormonalReceptors, EstrogenRisk Assessment

Stichwörter der Autor:innen

21-gene recurrence scoreAdjuvant therapy benefitEarly-stage breast cancerHormone receptor positive breast cancerRisk of recurrence

Substanzen

Biomarkers, TumorAntineoplastic Agents, HormonalReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ncasasanta19@gmail.com.
  • Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.
  • Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Frank H. Netter School of Medicine at Quinnipiac University, Department of Medicine, Hamden, CT.
  • Department of Medicine, Division of Hematology and Medical Oncology, Northwell Cancer Institute, Riverhead, NY.

Förderung

  • Novartis Pharmaceuticals Corporation
  • Pfizer

Zitieren

APA

Casasanta, N., Patel, R., Raymond, S., Kier, M. W., Blanter, J., Sohval, S., Hovstadius, M., Wu, C., Zimmerman, B., Cascetta, K., Bagiella, E., & Tiersten, A. (2024). Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.06.005

Vancouver

Casasanta N, Patel R, Raymond S, Kier MW, Blanter J, Sohval S, et al. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.06.005

BibTeX
@article{Casasanta2024,
  author = {Casasanta, Nicole and Patel, Rima and Raymond, Samantha and Kier, Melanie W and Blanter, Julia and Sohval, Sophie and Hovstadius, Malin and Wu, Catherine and Zimmerman, Brittney and Cascetta, Krystal and Bagiella, Emilia and Tiersten, Amy},
  title = {Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.06.005}
}
Kostenlos starten →